ISRCTN73232918CompletedNot Applicable
Primary prevention of rheumatoid arthritis
Jan van Breemen Instituut (Netherlands)0 sites80 target enrollmentStarted: December 20, 2005Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 80
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Age 18 - 70 years for RF+, 18+ for aCCP
- •2. Twice increased Immunoglobulin M (IgM)-RF and/or aCCP with 4+ weeks interval
- •3. Human Leukocyte Antigen (HLA)-DR Shared Epitope (SE) positive
Exclusion Criteria
- •Situations with possible false positive RF:
- •1. Auto-immune diseases
- •2. Active infection with hepatitis C or Ebstein Barr virus
- •3. Recent chemotherapy
- •4. Co-morbidity with decreased life expectancy
- •5. Corticosteroid use for another disease
- •6. Contra-indications for corticosteroids: diabetes mellitus, osteoporosis
- •7. Pregnancy or lactation
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.EUCTR2009-010955-29-NLDivision of Clinically Immunology and Rheumatology, AMC
Not yet recruiting
Not Applicable
Prevention of RA by B cell directed therapy.pre-clinical RANL-OMON28176Academic Medical Center/University of Amsterdam, Amsterdam90
Recruiting
Not Applicable
Primary prevention of rheumatoid arthritis.rheumatoid arthritisNL-OMON26301Prof.dr. B.A.C. DijkmansVUMC/Jan van Breemen Instituut80
Completed
Not Applicable
Active management of rheumatoid arthritis (RA)ISRCTN78142229Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)100
Completed
Phase 3
Prevention of rheumatoid arthritis by atorvastatin in seropositive arthralgia patients: a multi-center doubleblind randomized placebo-controlled trialarthritis10003816rheumatoid arthritisNL-OMON44914Reade